Burning Rock Biotech (BNR) Cash & Equivalents (2019 - 2026)

Burning Rock Biotech's Cash & Equivalents history runs 8 years deep, the most recent figure standing at $69.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 3.07% year-over-year to $69.7 million; the TTM figure through Mar 2026 stood at $69.7 million (down 3.07% YoY), while the FY2025 annual figure was $68.4 million, down 3.95% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $69.7 million, up from $67.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $227.0 million in Q1 2022, with the low at $65.2 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $85.4 million (2023), against an average of $105.4 million.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents sank 47.4% in 2022, then dropped 3.07% in 2026.
• Burning Rock Biotech's Cash & Equivalents stood at $127.3 million in 2022, then tumbled by 32.9% to $85.4 million in 2023, then declined by 15.29% to $72.4 million in 2024, then fell by 6.8% to $67.4 million in 2025, then advanced by 3.4% to $69.7 million in 2026.
• Business Quant data shows BNR's Cash & Equivalents at $69.7 million in Q1 2026, $67.4 million in Q4 2025, and $65.2 million in Q3 2025.